Business
KDA GROUP ANNOUNCES A COLLABORATION TO INTEGRATE NEW CLINICAL ALERTS INTO THE MEDHERIZE PLATFORM TO SUPPORT THE ADOPTION OF NEXT-GENERATION SEQUENCING FOR BREAST CANCER PATIENTS
KDA GROUP ANNOUNCES A COLLABORATION TO INTEGRATE NEW CLINICAL ALERTS INTO THE MEDHERIZE PLATFORM ...
About this update from Kda Group Inc.
[{"type":"text","content":"\n\n\nKDA GROUP ANNOUNCES A COLLABORATION TO INTEGRATE NEW CLINICAL ALERTS INTO THE MEDHERIZE PLATFORM TO SUPPORT THE ADOPTION OF NEXT-GENERATION SEQUENCING FOR BREAST CANCER PATIENTS\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\nCanada NewsWire\n\n\n\nTHETFORD MINES, QC, Dec. 22, 2025 /CNW/ - KDA Group Inc. (TSXV: KDA) (\"KDA\" or the \"Corporation\"), a leader in innovative technological solutions for healthcare professionals, is pleased to announce a collaboration with AstraZeneca Canada to support the utility of next-generation sequencing (\"NGS\") diagnostic testing for patients with metastatic breast cancer at Hôpital du Saint-Sacrement (CHU de Québec – Université Laval). NGS enables parallel analysis of multiple tumor genes to identify clinically actionable biomarkers and support faster, more informed treatment decisions.\nThe collaboration agreement is non-material, is made effective as of December 2, 2025, and provides for an initial term that may be extended to three years should the project demonstrate successful outcomes.\nThis initiative will be delivered through Medherize, KDA's digital platform, integrated with the Québec Health Record (Dossier Santé Québec – \"DSQ\"). Medherize consolidates laboratory results, clinical alerts and patient-reported information into a single workflow for clinicians. By facilitating timely access to genomic testing, the project advances evidence-based practice and helps ensure patients receive timely, safe and personalized care.\nThe collaboration agreement aims to integrate targeted digital notifications (alerts) within Medherize to support clinicians in optimizing compliance with NGS testing, in alignment with appropriate clinical milestones. These alerts are intended to prompt timely testing, interpretation, and clinical action, thereby supporting consistent adoption of precision oncology practices across the care continuum.\nThis approach also aligns with the Quebec Ministry of Health and Social Services' new framework aimed at optimizing the practices of community pharmacists r...